

# Sultanate of Oman

## Ministry of Health

Directorate General of Pharmaceutical Affairs  
and Drug Control

MUSCAT



سِيَّاطِنَا جَمَانَا  
وَزَارَةُ الصِّحَّةِ  
الدَّيْرِ فِي الْعَامَةِ لِلصِّدْقِ  
وَالرَّقَابَةِ الدَّوْلِيَّةِ  
مَسْقَط

Director General of Royal Hospital  
Director General of Khoula Hospital  
Director General of Medical Supplies (MOH)  
Director General of Pvt. Health Est. Affairs (to kindly arrange distribution to all Pvt. Health Institutions)  
Director General of Health Services in all Governorates  
Director of Rational Use of Medicine (MOH)  
Hospital Director (Al Nahda Hospital)  
Hospital Director (Al Massara Hospital)  
The Head of Medical Services in SQU Hospital  
The Head of Medical Services in Royal Oman Police  
The Head of Medical Services in Ministry of Defence  
The Head of Medical Services in The Diwan  
The Head of Medical Services in The Sultan's Special Force  
The Head of Medical Services in Internal Security Services  
The Head of Medical Services in Petroleum Development of Oman  
The Head of Medical Services in LNG Oman  
Director of Pharmacy & Medical Stores in all Governorate (for distribution pls.)  
ALL PRIVATE PHARMACIES & DRUG STORES

After Compliments,

Please find attached our Circular No. 17..... dated 28/2/18  
regarding the voluntary recall of different batches of Lynparza (Olaparib)  
50mg Capsules by AstraZeneca.

Copy to:

- Director, Office of H.E. The Undersecretary for Health Affairs
- Director of Pharmacovigilance & Drug Information Dept, DGPA&DC
- Director of Drug Control Department, DGPA&DC
- Director of Pharmaceutical Licensing Department, DGPA&DC
- Director of Central Quality Control Lab., DGPA&DC
- Director of Medical Device Control, DGPA&DC
- Supdt. of Central Drug Information
- Head of Cordin. & FU

# Sultanate of Oman

## Ministry of Health

Directorate General of Pharmaceutical Affairs  
and Drug Control

MUSCAT



سلطنة عمان  
وزارة الصحة  
الديرة العامة للصيد  
والرقابة الدوائية  
مسقط

Circular No. \ / 2018

12 -06-1439 H

28 -02-2018

### Recall of different batches of Lynparza (50mg, Olaparib) Capsules M/s. AstraZeneca

Please be informed that M/s. AstraZeneca has voluntarily recalled the following batches of Lynparza Capsules 50mg (Olaparib) from certain countries. The recall was based on Out of Trend (OOT) results maintaly obtained during analysis of Polymorph L in Lynparza capsule identified in certain batches distributed to some countries worldwide.

NC047	NK719	NJ980	NJ166	NK718	NF380	NF413	NG657	JK0147
NC045	NJ015	NG592	NJ972	NK720	NF520	NF893	NG014	NJ810
NF924	JH0341	NG699	NG591	JH0342	JC0391	NF712	NG328	NK137
NG143	JH0147	NG893	NF381	NK349	NC955	NF668	NK347	NK518
NG196	NG944	NJ043	NG695	NK769	NG298	NF848	NG656	NK532
NG329	NJ137	NJ378	NG712	NG327	NG086	NF944	NG895	JL0184
NF922	NJ622	NJ478	NG902	NR730	JC04U2	NG085	NG848	
NG213	NK591	NJ533	NJ831	NK249	NF190	NG399	NJ132	
NG398	HN0406	NJ748	NK066	NJ254	NF894	NJ377	NJ133	
NR497	NG852	NK380	NK136	NF300	NG087	NG532	NJ141	

According to our records, none of the affected batches is imported to Oman, however, we are issuing this circular for your information and further precautions.

The healthcare professionals are kindly requested to report any adverse events or side effects associated with the use of any medicinal product to the Department of Pharmacovigilance & Drug Information in DGPA&DC.

Dr. Mohammed Hamdan Al Rubaie  
DIRECTOR GENERAL

